109170 ⎘
Structure or type of the nucleic acid; Chemical structure of the sugar 2'-O-R Modification
Antisense oligomers and uses thereof
#1802Modulation of angiopoietin-like 3 expression
#1803Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#1804Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#1805Methods and compositions for inhibiting PMP22 expression
#1806Nucleic acid-polypeptide compositions and uses thereof
#1807Nucleic acid-polypeptide compositions and uses thereof
#1808Approach for treating inflammatory disorders
#1809COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION
#1810LNA-G Process
#1811Compositions and methods for inhibiting expression of CD274/PD-L1 gene
#1812MODULATORS OF COMPLEMENT FACTOR B
#1813Oligomers
#1814Aptamers for consumer product compositions
#1815Post-transcriptionally chemically modified double strand RNAs
#1816Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
#1817Structure-guided chemical modification of guide RNA and its applications
#1818TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#1819Post-transcriptionally chemically modified double strand RNAs
#1820Antisense nucleic acids
#1821MODULATION OF ENHANCER RNA MEDIATED GENE EXPRESSION
#1822Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof
#1823Targeted RNA editing
#1824Modified RNAi agents
#1825High density lipoprotein binding protein (Hdlbp/Vigilin) iRNA compositions and methods of use thereof
#1826MEANS FOR LUNG SPECIFIC DELIVERY
#1827RNA complexes that inhibit melanin production
#1828Methods for performing antisense oligonucleotide-mediated exon skipping in the retina of a subject in need thereof
#1829Stem-loop compositions and methods for inhibiting factor D
#1830SYNTHETIC GUIDE RNA FOR CRISPR/CAS ACTIVATOR SYSTEMS
#1831NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY
#1832Ribonucleic acid aptamer having inhibitory effect on non-small cell lung cancer and pharmaceutical composition comprising same
#1833Methods for performing multiplexed real-time PCR in a self-contained nucleic acid analysis pouch
#1834Interfering RNA molecules
#1835Polynucleotide agents targeting factor XII (hageman factor) (F12) and methods of use thereof
#1836Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity
#1837Two-tailed self-delivering siRNA
#1838Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease
#1839Antisense oligonucleotides for the treatment of Usher syndrome type 2
#1840Methods for modulating Ataxin 2 expression
#1841Compositions and methods for modulating angiopoietin-like 3 expression
#1842COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE
#1843COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
#1844Monocarboxylate transporter 4 (MCT) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer
#1845Anti-ADAM33 oligonucleotides and related methods
#1846Methods of treating cancer by inhibition of DNA repair proteins using antisense based therapies
#1847DOUBLE-STRANDED OLIGONUCLEOTIDES
#1848Methods and compositions for the specific inhibition of β-catenin by double-stranded RNA
#1849SELECTIVE REDUCTION OF ALLELIC VARIANTS
#1850Nucleic acid-polypeptide compositions and uses thereof
#1851Compositions and methods for inhibiting HMGB1 expression
#1852Polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) and methods of use thereof
#1853RNA interference in dermal and fibrotic indications
#1854Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#1855Compositions and methods for modulation of IKBKAP splicing
#1856Nucleic acid-polypeptide compositions and uses thereof
#1857Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
#1858Methods and compositions for managing vascular conditions
#1859Compositions and Methods for Inhibition of Expression of Apolipoprotein C-III (APOC3) Genes
#1860RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
#1861Compositions and methods for immunooncology
#1862RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy
#1863MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes
#1864Organic compositions to treat beta-ENaC-related diseases
#1865Mobilizing leukemia cells
#1866MicroRNA Compounds and Methods for Modulating MIR-21 Activity
#1867Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
#1868Serpina1 iRNA compositions and methods of use thereof
#1869Methods of reducing expression of X-inactivation escapee genes and autosomal genes
#1870Compositions and their uses directed to huntingtin
#1871siRNA and their use in methods and compositions for inhibiting the expression of the NRARP gene
#1872Splice-switching oligonucleotides and methods of use
#1873Treatment of age-related macular degeneration using RNA complexes that target MyD88 or TLR3
#1874RNA interference in skin indications
#1875Antisense Polynucleotides to Induce Exon Skipping and Method of Treating Dystrophies
#1876COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION
#1877RIG-I ligands and methods for producing them
#1878COMPOUNDS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION FOR IMPROVING A DIABETIC PROFILE
#1879METHODS AND COMPOSITIONS FOR PREVENTING ISCHEMIA REPERFUSION INJURY IN ORGANS
#1880Antisense oligonucleotides for the treatment of leber congenital amaurosis
#1881MicroRNA Compounds and Methods for Modulating MIR-21 Activity
#1882Targeting MicroRNAs for the Treatment of Fibrosis
#1883Linkage modified oligomeric compounds
#1884Methods for Treatment of Alport Syndrome
#1885COMPOSITIONS AND METHODS FOR MODULATING SMN GENE FAMILY EXPRESSION
#1886Interfering RNA molecules
#1887Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
#1888COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
#1889Oligonucleotides for modulating gene expression and uses thereof
#1890ORGANIC COMPOSITIONS TO TREAT BETA-CATENIN-RELATED DISEASES
#1891Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
#1892Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion
#1893Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA
#1894Compositions and methods for modulating apolipoprotein (a) expression
#1895Compositions and methods for modulating apolipoprotein C-III expression
#1896MODULATION OF TRANSTHYRETIN EXPRESSION
#1897Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
#1898MODULATION OF TRANSTHYRETIN EXPRESSION
#1899Compositions and their uses directed to huntingtin
#1900Modulation of SMN expression
#1901Compounds and methods for modulation of DUX4
#1902MODULATORS OF KRAS EXPRESSION
#1903AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#1904Antisense nucleic acids
#1905METHODS FOR THE TREATMENT OF ALOPECIA AREATA UTILIZING GENE MODULATION APPROACHES
#1906Renal selective inhibition of cytochrome P450 3A5
#1907PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders
#1908Compositions and Methods for Inhibiting Gene Expression of Alpha-1 AntiTrypsin
#1909Modified iRNA agents
#1910Compositions and methods for modulating Ataxin 3 expression
#1911Methods and compositions for modulating apolipoprotein (a) expression
#1912Targeting microRNAs for metabolic disorders
#1913Oligomeric compounds comprising bicyclic nucleotides and uses thereof
#1914Compositions and methods for inhibiting expression of ADAMTS-5 and ADAM17
#1915COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#1916Antisense oligonucleotides to treat Dystrophic Epidermolysis Bullosa
#1917COMPOSITIONS AND METHODS FOR TREATING HYPERTRIGLYCERIDEMIA
#1918MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPODYSTROPHY POPULATIONS
#1919Notch 1 specific siRNA molecule
#1920UNA oligomers for therapeutics with prolonged stability
#1921Methods and compositions for modlating apolipoprotein (A) expression
#1922ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
#1923Modified TGF-beta oligonucleotides
#1924Compositions and methods for inhibiting gene expression of Hif2alpha
#1925Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
#1926METHODS FOR TREATING TUMORS
#1927METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#1928NUCLEIC ACID COMPLEX HAVING AT LEAST ONE BULGE STRUCTURE
#1929Modulation of TMPRSS6 expression
#1930Interfering RNA molecules
#1931Compositions and methods for modulating MECP2 expression
#1932NUCLEIC ACID COMPLEX
#1933THERAPEUTIC OLIGONUCLEOTIDES
#1934Compositions and methods for inhibiting expression of the PCSK9 gene
#1935XANTHINE DEHYDROGENASE (XDH) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1936Oligonucleotide compositions and methods thereof
#1937Oligonucleotides matching COL7A1 exon 73 for epidermolysis bullosa therapy
#1938TREATMENT OF LIPID TRANSPORT AND METABOLISM GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A LIPID TRANSPORT AND METABOLISM GENE
#1939Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
#1940Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (PNPLA3) and methods of use thereof
#1941Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)
#1942COMPOUNDS AND METHODS FOR MODULATING TARGET NUCLEAR AND SUB-NUCLEAR NUCLEIC ACID MOLECULES IN CELLS AND ANIMALS
#1943Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
#1944Micromirs
#1945Compositions and methods for inhibiting expression of RRM2 genes
#1946Glucokinase (GCK) iRNA compositions and methods of use thereof
#1947RNA interference mediated inhibition of hepatitis B Virus (HBV) gene expression using short interfering nucleic acid (siNA)
#1948Compositions and methods for inhibiting gene expression of LPA
#1949Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
#1950Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer
#1951DISCONTINUOUS OLIGONUCLEOTIDE LIGANDS
#1952Pharmaceutical Composition
#1953METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER
#1954Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
#1955OLIGONUCLEOTIDE TARGETING STRATEGY FOR cccDNA
#1956MODULATION OF TRANSTHYRETIN EXPRESSION
#1957MODULATION OF TRANSTHYRETIN EXPRESSION
#1958MODULATION OF TRANSTHYRETIN EXPRESSION
#1959MODULATION OF TRANSTHYRETIN EXPRESSION
#1960MODULATION OF TRANSTHYRETIN EXPRESSION
#1961MODULATION OF TRANSTHYRETIN EXPRESSION
#1962MODULATION OF TRANSTHYRETIN EXPRESSION
#1963MODULATION OF TRANSTHYRETIN EXPRESSION
#1964MODULATION OF TRANSTHYRETIN EXPRESSION
#1965MODULATION OF TRANSTHYRETIN EXPRESSION
#1966CRISPR-BASED COMPOSITIONS AND METHODS OF USE
#1967Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
#1968Targeting microRNAs for metabolic disorders
#1969Antisense molecules and methods for treating pathologies
#1970siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis
#1971Micro-RNA family that modulates extracellular matrix genes and uses thereof
#1972Method for generating aptamers with improved off-rates
#1973Materials and methods for modulation of tendon healing
#1974Restoration of the CFTR function by splicing modulation
#1975RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
#1976ORGANIC COMPOSITIONS TO TREAT KRAS-RELATED DISEASES
#1977RNAi inhibition of alpha-ENaC expression
#1978UNA oligomers and compositions for treating amyloidosis
#1979Chemical modification of short small hairpin RNAs for inhibition of gene expression
#1980Dual Targeting siRNA Agents
#1981Compounds and methods for increasing antisense activity
#1982Single-stranded oligonucleotides for use in the medical treatment of skin disorders
#1983Antisense nucleic acids
#1984MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION
#1985Methods for modulating expression of C9ORF72 antisense transcript
#1986Compositions and methods for inhibiting expression of the LECT2 gene
#1987Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
#1988Nucleic acid aptamers to treat histone-induced disease states
#1989Modulation of nuclear-retained RNA
#1990Targeting microRNAs for the treatment of liver cancer
#1991ANTISENSE COMPOUNDS TARGETING GENES ASSOCIATED WITH FIBRONECTIN
#1992Antisense compounds targeting genes associated with cystic fibrosis
#1993Methods for treating acute myeloid leukemia and nanoparticle complexes of miR-22 utilized therein
#1994Chemically modified guide RNAs for CRISPR/CAS-mediated gene regulation
#1995Antisense compounds targeting genes associated with cystic fibrosis
#1996Targeting hepatitis B virus (HBV) host factors
#1997Treatment of genetic disorders associated with DNA repeat instability
#1998Compounds and methods for modulating TMPRSS6 expression
#1999Therapeutic UNA oligomers and uses thereof
#2000Short interfering nucleic acid (siNA) compositions
#2001RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
#2002Organic compositions to treat EPAS1-related diseases
#2003Factor XII (Hageman Factor) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#2004Oligonucleotide compounds for targeting huntingtin mRNA
#2005Inhibitors of MYH7B and uses thereof
#2006Compositions for modulating Tau expression
#2007EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS
#2008Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, HAO1) and methods of use thereof
#2009TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#2010MODIFIED TGF-BETA2 OLIGONUCLEOTIDES
#2011Modulation of huntingtin expression
#2012Compositions and methods for correcting limb girdle muscular dystrophy type 2C using exon skipping
#2013Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
#2014MIRNA MIMETICS AND THEIR USE IN TREATING SENSORY CONDITIONS
#2015Micro-RNA inhibitors and their uses in disease
#2016Modulation of alpha synuclein expression
#2017NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS
#2018MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
#2019RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Neuromuscular Disorders
#2020Compositions and methods for inhibition of expression of protein C (PROC) genes
#2021Targeting ligands
#2022siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAi, and stabilized forms thereof
#2023Compositions and methods for inhibition of nucleic acids function
#2024Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease
#2025Compositions and methods for modulating Tau expression
#2026ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
#2027Guide RNA with chemical modifications
#2028HER2 aptamer-anticancer drug complex for cancer cell chemotherapy
#2029HER2 aptamer-anticancer drug complex for cancer cell chemotherapy
#2030Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same
#2031Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
#2032Composition for treating cancer associated with HPV infection
#2033Compositions and methods for modulating TTR expression
#2034DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO P53 AND METHODS OF USE THEREOF
#2035ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHODS OF TREATING DYSTROPHIES
#2036Compositions and methods for inhibiting expression of the ALAS1 gene
#2037RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
#2038TARGETING OLIGONUCLEOTIDES AND USES THEREOF TO MODULATE GENE EXPRESSION
#2039Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
#2040Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
#2041APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS
#2042siRNA compounds comprising terminal substitutions
#2043Acyl-amino-LNA and/or hydrocarbyl-amino-LNA oligonucleotides
#2044COATED CHITOSAN-BASED POLYPLEX FOR DELIVERY OF NUCLEIC ACIDS
#2045IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
#2046Disulfide-containing alkyne linking agents
#2047Compositions for modulating expression of C9ORF72 antisense transcript
#2048Compositions and methods for silencing hepatitis B virus gene expression
#2049Nucleic acid compounds for binding growth differentiation factor 8
#2050Methods for the treatment of Leber congenital amaurosis
#2051Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#2052Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof
#2053METHODS AND COMPOSITIONS FOR TREATING MALIGNANT TUMORS ASSOCIATED WITH KRAS MUTATION
#2054Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#2055COMPOUNDS AND METHODS FOR IMPROVED CELLULAR UPTAKE OF ANTISENSE COMPOUNDS
#2056Reducing intron retention
#2057COMPOSITIONS AND METHODS
#2058MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
#2059FULLY STABILIZED ASYMMETRIC SIRNA
#2060RNA targeting in alpha-synucleinopathies
#2061Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
#2062Methods for treatment of alport syndrome
#2063EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#2064EGFR nucleic acids and uses thereof
#2065Modulation of UBE3A-ATS expression
#2066Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
#2067Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
#2068Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#2069Modulation of alternative MDM2 splicing
#2070ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
#2071High specificity genome editing using chemically modified guide RNAs
#2072Conjugated antisense compounds and their use
#2073Hepatitis D virus (HDV) iRNA compositions and methods of use thereof
#2074Hepatitis B virus (HBV) iRNA compositions and methods of use thereof
#2075NUCLEIC ACID COMPLEX, METHOD FOR FORMING NUCLEIC ACID HYBRIDIZATION, PHARMACEUTICAL COMPOSITION, NUCLEIC ACID PROBE, AND COMPLEMENTARY-STRAND NUCLEIC ACID COMPLEX
#2076METHODS FOR TREATING HYPERCHOLESTEROLEMIA
#2077RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#2078ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF LEBER CONGENITAL AMAUROSIS
#2079Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
#2080Antisense oligonucleotide modulators of serotonin receptor 2C and uses thereof
#2081ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF
#2082Methods and compositions for preventing ischemia reperfusion injury in organs
#2083Compounds and methods for the modulation of COMP
#2084Organic compositions to treat Beta-ENaC-related diseases
#2085Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4
#2086Decoy oligonucleotides for the treatment of diseases
#2087Selective Reactivation of Genes on the Inactive X Chromosome
#2088RNA interference mediating small RNA molecules
#2089Modulation of AGPAT5 expression
#2090Compositions and methods for inhibiting expression of transthyretin
#2091Antisense nucleic acids
#2092Beta-catenin nucleic acids and uses thereof
#2093Modulation of prekallikrein (PKK) expression
#2094Modified TGF-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease
#2095Anti-TNF compounds
#2096METHODS AND COMPOSITIONS FOR INHALATION DELIVERY OF CONJUGATED OLIGONUCLEOTIDE
#2097MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes
#2098Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor
#2099Organic compositions to treat HSF1-related diseases
#2100MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD